8-K: Scorpius Holdings Secures $750,000 Loan and Restructures Existing Debt

Scorpius Holdings has entered into a note purchase agreement for a $750,000 loan and restructured a prior convertible note, extending its maturity and adjusting conversion terms.

Summary

• Scorpius Holdings, Inc. has secured a $750,000 loan from Elusys Holdings Inc. through a promissory note with a 1% annual interest rate.
• The loan matures on July 1, 2024, and the full principal and accrued interest are due on this date.
• The company also amended and restated a previous $2,250,000 convertible promissory note, extending its maturity to September 1, 2025.
• The conversion price of the restated note is set at 110% of the volume-weighted average price (VWAP) of the company's common stock for the seven trading days prior to December 11, 2023, which was $0.39109.
• If Scorpius completes a public financing within 60 days of May 1, 2024, the conversion price will be adjusted to 110% of the per-share price in that financing.
• The restated note can only be converted into common stock if shareholder approval and NYSE American LLC approval are obtained.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the short-term debt and restructuring of existing debt, indicating potential financial challenges. However, the company has secured funding and extended the maturity of a significant debt, which is a positive.

Positives

• The company has secured immediate funding of $750,000.
• The restructuring of the $2,250,000 convertible note extends the repayment timeline to September 1, 2025, providing more financial flexibility.
• The potential adjustment of the conversion price in the restated note could be beneficial if the company secures a public financing at a higher price.

Negatives

• The $750,000 loan is due in full on July 1, 2024, which could create a short-term repayment challenge.
• The conversion of the restated note is contingent on shareholder and NYSE American LLC approval, which introduces uncertainty.
• The initial conversion price of the restated note is based on a historical VWAP, which may not reflect the current market value of the stock.

Risks

• The company faces the risk of default if it cannot repay the $750,000 loan by July 1, 2024.
• Failure to obtain shareholder and NYSE American LLC approval for the conversion of the restated note could impact the company's capital structure.
• The conversion price adjustment is dependent on a public financing event, which may not occur within the specified timeframe.
• The company's ability to meet its financial obligations is dependent on its ability to generate sufficient cash flow or secure additional funding.

Future Outlook

The company's future financial stability is dependent on its ability to repay the $750,000 loan by July 1, 2024, and potentially convert the restated note into equity, subject to shareholder and NYSE American LLC approval. The company may also seek a public financing within 60 days of May 1, 2024, which could impact the conversion price of the restated note.

Management Comments

• The documents do not contain direct quotes from management, but the agreements were signed by William Ostrander, CFO, and Jeffrey Wolf, CEO.

Industry Context

This announcement reflects a common practice for smaller companies to secure short-term financing through promissory notes and restructure existing debt to manage cash flow. The reliance on convertible notes is also typical for companies seeking to raise capital while avoiding immediate dilution.

Comparison to Industry Standards

• The 1% interest rate on the promissory notes is relatively low, suggesting the lender has a strong relationship with the company, likely due to the lender being controlled by the company's Chairman, CEO and President.
• The use of convertible notes with a conversion price tied to a historical VWAP and potential adjustment based on future financing is a common structure in the small-cap market.
• The requirement for shareholder and exchange approval for conversion is standard practice to ensure compliance with listing rules and protect shareholder interests.
• Companies like Cassava Sciences (SAVA) and Amylyx Pharmaceuticals (AMLX) have also used convertible notes as a financing tool, but the specific terms and conditions vary based on the company's financial situation and market conditions.

Related Party Transactions

• The loan and note restructuring are with Elusys Holdings Inc., which is controlled by the company's Chairman, Chief Executive Officer, and President, Jeffrey Wolf.

Stakeholder Impact

• Shareholders face potential dilution if the restated note is converted into common stock.
• Creditors are impacted by the new loan and the restructuring of the existing debt.
• Employees may be affected by the company's financial stability and future funding.

Next Steps

• The company needs to repay the $750,000 loan by July 1, 2024.
• The company needs to obtain shareholder and NYSE American LLC approval for the conversion of the restated note.
• The company may pursue a public financing within 60 days of May 1, 2024, to potentially adjust the conversion price of the restated note.

Key Dates

Keywords

promissory note, convertible note, loan, financing, debt, conversion price, shareholder approval, NYSE American, maturity date, Scorpius Holdings